Hannah and Angelos are joined by Dr Emma Magavern to discuss how DNA can impact our response to medicines, and how the latest science can be used to predict and prevent adverse drug reactions.
Dr Magavern is a Clinical Pharmacology Registrar in London and a PhD candidate at the William Harvey Research Institute, QMUL, working with Professor Mark Caulfield. She completed a BA in English prior to her MD and subsequent MScs in Bioethics and Genomics. Through training in clinical medicine, humanities, genetics and pharmacology she has developed an interest in the scientific merits, clinical potential and implementation challenges of pharmacogenomics. She was co-secretary of the RCP/BPS working group on pharmacogenomics and led the ESC pharmacotherapy working group pharmacogenomics position paper.
If our podcast has helped spark your interest in genetics, medicine, or broader science, then we are very humbled.
To ask us more about DNA or further study, please reach out via our contact form or Twitter. You can learn more about the research from our Institution at the Imperial College London website.
We would like to extend our special thanks to The Genetics Society and The Society for Endocrinology whose funding has helped to make this podcast possible.
© 2023 DNA& | Web design by oxford web builders | all rights reserved